Case Report
Copyright ©2007 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2007; 13(26): 3638-3640
Published online Jul 14, 2007. doi: 10.3748/wjg.v13.i26.3638
Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a
Eckart Schott, Friedemann Paul, Jens T Wuerfel, Frauke Zipp, Birgit Rudolph, Bertram Wiedenmann, Daniel C Baumgart
Eckart Schott, Bertram Wiedenmann, Daniel C Baumgart, Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical School, Humboldt-University of Berlin, Germany
Friedemann Paul, Jens T Wuerfel, Frauke Zipp, Cecilie-Vogt-Clinic for Molecular Neurology, Charité Medical School, Humboldt-University of Berlin, Germany
Birgit Rudolph, Department of Pathology, Charité Medical School, Humboldt-University of Berlin, Germany
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Daniel C Baumgart, MD, PhD, Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical Center-Virchow Hospital, Medical School of the Humboldt-University of Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. daniel.baumgart@charite.de
Telephone: +49-30-450553277 Fax: +49-30-450553983
Received: January 31, 2007
Revised: February 2, 2007
Accepted: March 8, 2007
Published online: July 14, 2007
Abstract

To alert clinicians to a potential novel adverse drug effect of interferonβ 1a, we herein report a patient with relapsing-remitting multiple sclerosis who developed ulcerative colitis following treatment with interferonβ 1a. Ulcerative colitis persisted despite discontinuation of interferonβ 1a treatment and switching the patient to glatiramer acetate. Tacrolimus (FK506), 6-mercaptopurine, and prednisolone were required to induce remission. Both ulcerative colitis and multiple sclerosis were eventually well controlled using this regimen. Our report underscores that caution should be exercised when prescribing immunostimulatory agents in patients with inflammatory bowel disease (IBD) and challenges current efforts to stimulate innate immunity as a novel therapeutic concept for IBD.

Keywords: Ulcerative colitis; Interferonβ 1a; Tacrolimus; Innate immunity; Multiple sclerosis; Adverse drug effects